Page 10 - mCSPC EN Booklet-Feb 2021 Web

Managing Metastatic Castration-

Naïve and Castration-Sensitive
Prostate Cancer

Course of Disease

Over the past few decades, clinical research has better defined the various phases
of the prostate cancer disease continuum. This has translated to important changes
in disease assessment, staging, treatment, and monitoring of advanced prostate
cancer. Recent therapeutic advances have not only extended overall survival
milestones, but have brought forth the importance of intermediate goals such as
delaying the progression of prostate cancer from a castration-sensitive state (often
referred to historically as hormone-sensitive prostate cancer) to a castration-
resistant state.

Prostate Cancer Disease Continuum and Clinical Trial Landscape

CHAARTED Docetaxel + ADT
de novo GETUG-AFU Docetaxel + ADT
metastasis STAMPEDE Docetaxel + ADT
Abiraterone + ADT
RT + ADT
LATITUDE Abiraterone + ADT
HORRAD RT + ADT
ARCHES Enzalutamide + ADT
ENZAMET Enzalutamide + ADT
TITAN Apalutamide + ADT
Metastatic
CSPC
Localized Metastatic
prostate CRPC
cancer
TAX327 Docetaxel + ADT
Non-metastatic Non-metastatic COU-AA-301 Abiraterone + ADT
COU-AA-302 Abiraterone + ADT
CSPC CRPC AFFIRM Enzalutamide + ADT
PREVAIL Enzalutamide + ADT
ADT PROSPER Enzalutamide + ADT TROPIC Cabazitaxel + ADT
SPARTAN Apalutamide + ADT ALSYMPCA Radium-223 + ADT
ARAMIS Darolutamide + ADT

Adapted from Aggarwal RR, et al. Oncology (Williston Park) 2017;31(6):467-74.
CRPC = castration-resistant prostate cancer; CSPC = castration-sensitive prostate cancer.

Practical Approaches to Managing mCNPC and mCSPC 7